(MDT) Medtronic - Ratings and Ratios
Pacemakers, Defibrillators, Stent Grafts, Insulin Pumps, Surgical Devices
MDT EPS (Earnings per Share)
MDT Revenue
Description: MDT Medtronic
Medtronic PLC is a leading global medical technology company that develops, manufactures, and sells a wide range of device-based medical therapies across various segments, including Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.
The companys diverse portfolio includes products such as implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices, as well as medical devices and implants for spinal surgeons, neurosurgeons, and other specialists. Medtronics products are designed to treat various diseases and conditions, including cardiovascular disease, neurological disorders, and diabetes.
From a financial perspective, Medtronic has a market capitalization of over $113 billion, indicating its significant presence in the healthcare industry. The companys return on equity (RoE) is around 9.62%, suggesting a relatively stable and profitable business model. Additionally, Medtronics forward price-to-earnings (P/E) ratio is approximately 15.85, which is relatively reasonable compared to its current P/E ratio of 24.45.
Some key performance indicators (KPIs) to monitor Medtronics performance include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. Medtronics revenue growth has been driven by its diversified portfolio and strategic acquisitions. The companys gross margin is around 68%, indicating a relatively high level of profitability. Medtronics R&D expenses account for around 8-9% of its revenue, demonstrating its commitment to innovation and new product development.
Other relevant KPIs for Medtronic include its debt-to-equity ratio, which is around 0.43, indicating a relatively conservative capital structure. The companys dividend yield is around 0.7%, which may be attractive to income-seeking investors. Overall, Medtronics diversified portfolio, stable financial performance, and commitment to innovation make it a significant player in the medical technology industry.
MDT Stock Overview
| Market Cap in USD | 116,723m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1978-01-13 |
MDT Stock Ratings
| Growth Rating | 0.69% |
| Fundamental | 64.7% |
| Dividend Rating | 61.6% |
| Return 12m vs S&P 500 | -8.60% |
| Analyst Rating | 3.81 of 5 |
MDT Dividends
| Dividend Yield 12m | 3.14% |
| Yield on Cost 5y | 3.02% |
| Annual Growth 5y | 4.12% |
| Payout Consistency | 97.6% |
| Payout Ratio | 41.6% |
MDT Growth Ratios
| Growth Correlation 3m | 88.1% |
| Growth Correlation 12m | 29% |
| Growth Correlation 5y | -51.8% |
| CAGR 5y | -0.21% |
| CAGR/Max DD 5y | 0.00 |
| Sharpe Ratio 12m | 0.97 |
| Alpha | -1.24 |
| Beta | 0.315 |
| Volatility | 23.35% |
| Current Volume | 5626.6k |
| Average Volume 20d | 6641.2k |
| Stop Loss | 89.2 (-3%) |
| Signal | 1.31 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (4.66b TTM) > 0 and > 6% of Revenue (6% = 2.01b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.61% (prev 34.44%; Δ -1.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 7.04b > Net Income 4.66b (YES >=105%, WARN >=100%) |
| Net Debt (26.30b) to EBITDA (9.22b) ratio: 2.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.29b) change vs 12m ago -2.84% (target <= -2.0% for YES) |
| Gross Margin 65.31% (prev 65.35%; Δ -0.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.92% (prev 35.97%; Δ 0.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.72 (EBITDA TTM 9.22b / Interest Expense TTM 729.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.03
| (A) 0.12 = (Total Current Assets 23.81b - Total Current Liabilities 12.88b) / Total Assets 91.68b |
| (B) 0.34 = Retained Earnings (Balance) 31.48b / Total Assets 91.68b |
| (C) 0.07 = EBIT TTM 6.36b / Avg Total Assets 90.83b |
| (D) 0.63 = Book Value of Equity 27.19b / Total Liabilities 43.42b |
| Total Rating: 3.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.68
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.63% = 1.81 |
| 3. FCF Margin 15.46% = 3.87 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 3.09 = -1.89 |
| 6. ROIC - WACC 1.08% = 1.35 |
| 7. RoE 9.62% = 0.80 |
| 8. Rev. Trend 75.81% = 3.79 |
| 9. Rev. CAGR 7.21% = 0.90 |
| 10. EPS Trend 14.18% = 0.35 |
| 11. EPS CAGR -1.13% = -0.14 |
What is the price of MDT shares?
Over the past week, the price has changed by +0.94%, over one month by -0.01%, over three months by +14.14% and over the past year by +7.56%.
Is Medtronic a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MDT is around 93.99 USD . This means that MDT is currently overvalued and has a potential downside of 2.21%.
Is MDT a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 98.4 | 7% |
| Analysts Target Price | 95.4 | 3.8% |
| ValueRay Target Price | 102.3 | 11.3% |
Last update: 2025-08-24 02:06
MDT Fundamental Data Overview
CCE Cash And Equivalents = 2.22b USD (last quarter)
P/E Trailing = 25.1657
P/E Forward = 16.7504
P/S = 3.4129
P/B = 2.4871
P/EG = 2.1889
Beta = 0.817
Revenue TTM = 33.54b USD
EBIT TTM = 6.36b USD
EBITDA TTM = 9.22b USD
Long Term Debt = 25.59b USD (from longTermDebt, last quarter)
Short Term Debt = 2.87b USD (from shortTermDebt, last quarter)
Debt = 28.46b USD (Calculated: Short Term 2.87b + Long Term 25.59b)
Net Debt = 26.30b USD (from netDebt column, last quarter)
Enterprise Value = 142.97b USD (116.72b + Debt 28.46b - CCE 2.22b)
Interest Coverage Ratio = 8.72 (Ebit TTM 6.36b / Interest Expense TTM 729.0m)
FCF Yield = 3.63% (FCF TTM 5.18b / Enterprise Value 142.97b)
FCF Margin = 15.46% (FCF TTM 5.18b / Revenue TTM 33.54b)
Net Margin = 13.90% (Net Income TTM 4.66b / Revenue TTM 33.54b)
Gross Margin = 65.31% ((Revenue TTM 33.54b - Cost of Revenue TTM 11.63b) / Revenue TTM)
Tobins Q-Ratio = 5.26 (Enterprise Value 142.97b / Book Value Of Equity 27.19b)
Interest Expense / Debt = 0.61% (Interest Expense 174.0m / Debt 28.46b)
Taxrate = 16.63% (from yearly Income Tax Expense: 936.0m / 5.63b)
NOPAT = 5.30b (EBIT 6.36b * (1 - 16.63%))
Current Ratio = 1.85 (Total Current Assets 23.81b / Total Current Liabilities 12.88b)
Debt / Equity = 0.59 (Debt 28.46b / last Quarter total Stockholder Equity 48.02b)
Debt / EBITDA = 3.09 (Net Debt 26.30b / EBITDA 9.22b)
Debt / FCF = 5.49 (Debt 28.46b / FCF TTM 5.18b)
Total Stockholder Equity = 48.46b (last 4 quarters mean)
RoA = 5.09% (Net Income 4.66b, Total Assets 91.68b )
RoE = 9.62% (Net Income TTM 4.66b / Total Stockholder Equity 48.46b)
RoCE = 8.58% (Ebit 6.36b / (Equity 48.46b + L.T.Debt 25.59b))
RoIC = 6.95% (NOPAT 5.30b / Invested Capital 76.24b)
WACC = 5.87% (E(116.72b)/V(145.19b) * Re(7.18%)) + (D(28.46b)/V(145.19b) * Rd(0.61%) * (1-Tc(0.17)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.20%
Discount Rate = 7.18% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.20% ; FCFE base≈5.19b ; Y1≈5.16b ; Y5≈5.41b
Fair Price DCF = 74.79 (DCF Value 95.82b / Shares Outstanding 1.28b; 5y FCF grow -1.29% → 3.0% )
Revenue Correlation: 75.81 | Revenue CAGR: 7.21%
Rev Growth-of-Growth: -0.63
EPS Correlation: 14.18 | EPS CAGR: -1.13%
EPS Growth-of-Growth: 6.50
Additional Sources for MDT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle